Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study - Wikidata - awgldk - TriplyDB

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

http://www.wikidata.org/entity/Q35043760

about

Insulin resistance in development and progression of nonalcoholic fatty liver disease Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease Bile acid receptors and nonalcoholic fatty liver disease Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study Impaired lung function is associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in middle-aged and elderly Chinese Impact of anthropometric cut-off values in determining the prevalence of metabolic alterations.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study.Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage.PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes.Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus.Practical approach to non-alcoholic fatty liver disease in patients with diabetes.Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice.Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study.Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases.Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease.Long-term follow-up of hepatic ultrasound findings in subjects with magnetic resonance imaging defined hepatic steatosis following clinical islet transplantation: a case-control study Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease Non-alcoholic fatty liver disease and diabetes.Racial/ethnic differences in hepatic steatosis in a population-based cohort of post-menopausal women: the Michigan Study of Women's Health Across the Nation.Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management.The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease.

P2860

Q26748687-2D4654E1-8EA1-4B64-A4B0-06723EFA8825 Q26771752-2F1C1AAF-C438-4630-A835-02A068202280 Q26775814-B1939D7C-2D89-4518-BF3B-B7B7561F0B20 Q26778426-B5C35553-F79C-46A3-9B6A-E7600C99C209 Q26827169-901F3CBC-05EE-41A2-8123-2B2077ADF18A Q26852019-DAC9190A-EA29-4FCE-A7C0-ABBC57FCE41E Q27006131-13F3A696-F4EF-4719-8734-59C995BA324B Q27318751-B62E5A95-AD97-45D7-90DD-A4E216DB0636 Q28595534-839BD3C0-D75E-499A-B28D-E78AED64095E Q28648219-3E26C07D-14F2-4BA8-8897-E782B0249784 Q29248598-7F94440A-11C0-4FA1-8335-C015BF1CC039 Q30244063-9ED79BD5-C9EC-4AE5-9AB0-815C1C6CB515 Q30366569-98DC5C27-C9C2-4B35-AAE1-C09C2BA3AA0C Q30366572-2F489732-5831-42CF-B410-980C3FC0532C Q30368624-6FD7AC02-82CD-4897-9B10-1554CDD2D111 Q30382172-7EF1F141-C7B9-4FB5-B87F-9741AC2B6B81 Q30577903-8797B634-F404-4235-B2BA-51DEEFAEF802 Q33751826-C48E74C2-3F7B-4139-8B5E-9CE1A4B3CAE3 Q33825128-F8E39427-D174-4A10-BE37-32FB8FF833FF Q33854492-323388C1-2520-42CF-AD9F-54F4A147775D Q34205386-CE4FC7A6-DB45-425E-AAB5-0E6C5C47F6B0 Q34303001-BB6C8B0B-52DD-4750-B7EC-F1CA3DB66537 Q34510307-C53163AF-77AD-420A-AF34-D098A5278D2F Q35088712-0BEA53EC-AAAF-46F9-B374-B58B48C92AE1 Q35561693-1214DF4C-4055-4FE0-BF6C-2DC1EA1281DA Q35605858-0C26CEB7-27B2-4C43-9AB3-D064C225A214 Q35769495-16FCA4B0-6AF8-40CF-9BE1-4A6D62030AA5 Q35926504-EE301E28-06A6-460D-938C-E2F8A9DBCDF0 Q35972690-7AA1BBE6-B633-4E70-9E46-9A44D291C0BF Q36060375-EF0ECBCF-97A1-4FF7-9451-D12BF9CAF9A4 Q36750183-D2BF9FC1-BE0E-494E-8785-46B989A334C4 Q36818830-E5ED1A4B-3317-4DE4-9F0E-7D234E8ACDAB Q36870361-8C0EA4EA-6989-4443-8B7A-FFD7D7E255B5 Q36872035-862B27DE-A962-4676-BE86-84055948362C Q36921610-56A00C7D-7A56-47F1-B59D-55B625C7B81C Q37091659-F5FAEE0D-2E8A-411B-91C0-B736F3699342 Q37204875-27FE3330-B66E-47FD-8556-85096C521992 Q37375539-4FFC1AE3-074C-4201-B4AF-405EFFF4EEA3 Q37406308-3B83F13E-3228-46C2-A5A1-A842D01198D3 Q37552230-D61F7D43-73DA-4A7C-95A9-947D64D0383B

P2860

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

http://www.wikidata.org/entity/Q35043760

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prevalence of and risk factors ...... dinburgh Type 2 Diabetes Study

@en

type

label

Prevalence of and risk factors ...... dinburgh Type 2 Diabetes Study

@en

prefLabel

Prevalence of and risk factors ...... dinburgh Type 2 Diabetes Study

@en

P1433

Q35043760-47691906-24DE-49D2-AE0E-FB9A79238412

P1476

Q35043760-53DA8677-B4A6-4119-8D41-409A4B5554F8

P2093

Q35043760-01963834-DDFC-4F16-84AD-09C490AB3D08

Q35043760-1AF8ABD0-283E-4AD8-A3C6-AA78A3616B0B

Q35043760-1F0B42C6-A7B9-4623-A01A-F817C4CFEAA5

Q35043760-32E86C65-05B6-4A2F-86A1-DB47F3E208DB

Q35043760-482EA15B-65D7-4D3B-9B57-D374F409628F

Q35043760-8AA83B75-A062-4A8A-ACC4-448E7C097198

Q35043760-980233D8-4559-47C9-9934-DEB6FDD7CA0F

Q35043760-99A014C4-8767-435B-B644-2DAFB08A148D

Q35043760-A2FF9F7C-BC16-4C96-AAEE-EB053C50A787

Q35043760-B3DFBAA6-1B1C-49EB-BC9D-B31B29B7BD98

P2860

Q35043760-14DB87BD-C027-4977-94D7-7A3CA0AE5245

Q35043760-2503BEF8-B732-46B8-A713-6B2AB50E6BC8

Q35043760-29C997CA-D1C4-461E-B2BF-DB2EDBD81BCC

Q35043760-3C0BB133-430B-4991-B391-EE5BA1C6C81B

Q35043760-4BF1ABDA-9CD2-4DCF-BB54-FF70604CEE33

Q35043760-59DE9C71-F19C-49CD-A691-66F2269019FF

Q35043760-5A99A6ED-FDAE-4D79-B935-19A209E8D6DA

Q35043760-5D4D0701-F924-4B17-8E6D-CA94E106BDF8

Q35043760-6751DB6A-1E57-4155-9EB8-D3571EC25273

Q35043760-68D39292-BEB8-4F94-B433-900F56A2D356

P304

Q35043760-90F91506-E54E-44F9-8201-2316790F0B30

P31

Q35043760-046A8F67-C3EE-49D9-ADE9-05ECF7B80A73

P356

Q35043760-37E8FDD1-512D-4624-A517-94A4BC09C36F

P407

Q35043760-76B5DA3D-0A3C-4926-9594-F941573D8AB0

P433

Q35043760-14BFDD08-F985-4420-AF44-63813146B74C

P478

Q35043760-D4655AEF-2C27-4904-B531-7C7CE109A4D2

P50

Q35043760-DC613927-AED8-48FA-8C03-4AD260D18D1D

P577

Q35043760-26B12128-22F1-457C-BF3C-CFEA12CC5CFA

P5875

Q35043760-D9206811-0D45-48F0-9341-C335F8077CD0

P698

Q35043760-A147AA93-6919-40E4-B6BD-282EE0869083

P921

Q35043760-A0E36E56-64A1-4A69-8629-539D9D0E9865

P932

Q35043760-489EF677-1C3E-42E9-816C-EB61E528B5A9

P356

P1433

P1476

Prevalence of and risk factors ...... dinburgh Type 2 Diabetes Study

@en

P2093

Brian M Frier

http://www.w3.org/2001/XMLSchema#string

Edinburgh Type 2 Diabetes Study Investigators

http://www.w3.org/2001/XMLSchema#string

Elisa Perry

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Johnston

http://www.w3.org/2001/XMLSchema#string

Jackie F Price

http://www.w3.org/2001/XMLSchema#string

Liesbeth A F Van Look

http://www.w3.org/2001/XMLSchema#string

Lisa D Nee

http://www.w3.org/2001/XMLSchema#string

Mark W J Strachan

http://www.w3.org/2001/XMLSchema#string

Peter C Hayes

http://www.w3.org/2001/XMLSchema#string

Rachel M Williamson

http://www.w3.org/2001/XMLSchema#string

P2860

The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

Nonalcoholic fatty liver disease

The Edinburgh Type 2 Diabetes Study: study protocol.

Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

AGA technical review on nonalcoholic fatty liver disease.

Diagnosis of fatty liver disease: is biopsy necessary?

P304

1139-1144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC10-2229

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Rebecca M Reynolds

P577

2011-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51037486

http://www.w3.org/2001/XMLSchema#string

P698

21478462

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3114489

http://www.w3.org/2001/XMLSchema#string